Table 1.

List of AML patients for the FACS screening and ex vivo/in vivo studies.

No.	Diagnosis	Disease Status	Age	Sex	Cytogenetics(Karyotype)	Gene Mutation
1	AML	Newly Diagnosed	32	F	Normal	FLT3, CEBPA and NPM1: NEGATIVE
2	AML	Newly Diagnosed	70	M	Normal	The molecular analyses of CEBPA, FLT3and NPM1 mutations show only positive for FLT3 internal tandem duplication mutation (FLT3-ITD)
3	AML	Diagnosed	35	M	Normal	FLT3, CEBPA and NPM1: NEGATIVE
4	AML	Newly Diagnosed	59	M	Normal	CEBPA negative; NPM mutation not detected; FLT3 ITD not detectedFLT3 TKD not detected
5	AML	Newly Diagnosed	53	M	inv(16)(p13.1q22) MYH11/CBFB	FLT3, CEBPA and NPM1: NEGATIVE
6	AML	Diagnosed	65	M	Normal	FLT3 ITD (+), CEBPA (-), NPM 1 (+), c kit (-), PML RARA
7	AML	Newly Diagnosed	45	M	Normal	CEBPA, DNMT3A, FLT3, IDH1/2, KIT, KRAS, NRAS, RUNX1 TP53
8	AML	Diagnosed	38	F	t(8;21) RUNX1-RUX1T1	Mutations noted in KRAS, NF1, and TP53; Negative for IDH 1, IDH2 and FLT3, RUNX1
9	AML	Diagnosed	30	M	Normal	Intermediate Risk (Wild type NPM1 without FLT3-ITD without adverse risk genetic lesions)
10	AML	Newly Diagnosed	33	F	Normal	DNMT3A, NRAS, NPM1
11	AML	Newly Diagnosed	78	M	Normal	TP53,U2AF1,ASXL1,RUNX1, FLT3-ITD
12	AML	Newly Diagnosed	53	M	46,XY,r(3)(p26q29),del(5)(q22q35),der(7)t(7;?;3)(q22;?;p11)[17]	TP53
13	AML	Newly Diagnosed	37	F	Normal	WT1, FLT3-ITD
14	AML	Newly Diagnosed	40	M	Normal	DNMT3A, IDH2, KRAs, NRAS,NPM1
15	AML	Newly Diagnosed	72	F	Normal	DNMT3A, TET2
16	AML	Newly Diagnosed	67	M	Normal	IDH2, NPM1
17	AML	Newly Diagnosed	20	M	46,XY,inv(16)(p13.1q22.1)[23]	KIT
18	AML	Newly Diagnosed	63	M	46,XY,i(21)(q10)[20]	RUNX1, WT1
19	AML	Newly Diagnosed	63	F	Normal	NPM1, SF3B1
20	AML	Newly Diagnosed	38	F	Normal	FLT3, WT1,NPM1,